front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |review

Based on LOCF analysis of data from all treated subjects, those receiving placebo demonstrated statistically significant (P<=0.05) mean increases from baseline in A1c. In patients receiving ACTOS, the mean decrease in A1c from baseline was statistically significant (P<=0.05), with the exception of the 7.5-mg group, at most timepoints. The difference in mean A1c at endpoint for the 45-mg once-daily dose group vs placebo was 1.6 percentage points. Aronoff S, et al. Diabetes Care. 2000;23:1605-1611.